

JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

[Log In](#)

[Submit](#)

[E-Alerts](#)

[Subscribe](#)

[OpenAthens/Shibboleth »](#)

Enter words / phrases / DOI / ISBN / authors / keywords / etc.

Search

Advanced Search

[Newest Articles](#)

[Issues](#)

[Browse By Topic](#)

[Special Content](#)

[Authors](#)

[Subscribers](#)

[About](#)

ASCO Journals

[PROSTATE CANCER](#)

Is clinical stage T2c prostate cancer intermediate- or high-risk disease? Results from the SEARCH database.

Abhay A Singh, Leah Gerber, Stephen J. Freedland, William J Aronson, Martha K. Terris, Joseph C. Presti, Christopher L Amling, Lionel Lloyds Banez, Shared Equal-Access Regional Cancer Hospital

OPTIONS & TOOLS

[Export Citation](#)

[Track Citation](#)

[Add To Favorites](#)

[Rights & Permissions](#)

Duke University Division of Urologic Surgery, Durham, NC; Duke University Medical Center and Durham VA Medical Center, Durham, NC; University of California, Los Angeles, Los Angeles, CA; Medical College of Georgia, Augusta, GA; Stanford University, Stanford, CA; Oregon Health and Science University, Portland, OR; Duke University Medical Center, Durham, NC

Show Less

Abstract

123

Background: Clinical stage T2c is a nebulous factor in the algorithm for prostate cancer risk stratification. According to D'Amico risk stratification cT2c is high-risk category where NCCN guidelines place this stage in intermediate-risk. As diagnostic work up with the use of MRI continues to escalate clinical staging may become more important. As cT2c represents a possible decision fork in treatment decisions we sought to investigate which risk group the clinical behavior of cT2c tumors more closely resembles.

Methods: We retrospectively analyzed data from 1089 men who underwent radical prostatectomy (RP) from 1988 to 2009 who did not have low-risk CaP from the SEARCH database. We compared time to BCR between men with cT2c disease, those with intermediate-risk (PSA 10-20 ng/ml or Gleason sum (GS) =7), and those with high-risk (PSA>20 ng/ml, GS 8-10, cT3) using Cox regression models adjusting for age, race, year of RP, center, and percent cores positive. We also

COMPANION ARTICLES

No companion articles

ARTICLE CITATION

DOI:

10.1200/jco.2012.30.5_suppl.123
Journal of Clinical Oncology 30,
no. 5_suppl (February 2012)
123-123.

PMID: 28143264

WE RECOMMEND

Is clinical stage T2c prostate cancer intermediate- or high-risk disease? Results from the SEARCH database.

Abhay A Singh et al., J Clin Oncol, 2012

Impact of the Percentage of Positive Prostate Cores on Prostate Cancer-Specific Mortality for Patients With Low or Favorable Intermediate-Risk Disease
Anthony V. D'Amico et al., J Clin

compared predictive accuracy of two Cox models wherein cT2c was considered either intermediate- or high-risk by calculating concordance index c .

Results: A total of 68 men (3.4%) had cT2c tumors. After a median follow-up of 47.5 months, there was no difference in BCR risk between men with intermediate-risk CaP and those with cT2c tumors (HR=0.90; $p=0.60$). In contrast, there was a trend for men with high-risk CaP to have nearly 50% increased BCR risk compared to men with cT2c tumors (HR=1.50; 95% CI=0.97-2.30; $p=0.07$) which did not reach statistical significance. Concordance index c was higher in the Cox model wherein cT2c tumors were considered intermediate-risk ($c=0.6147$) as opposed to high-risk ($c=0.6106$).

Conclusions: BCR risk for patients with clinical stage T2c was more comparable to men who had intermediate-risk CaP than men with high-risk. In addition, a model which incorporates cT2c disease as intermediate-risk has better predictive accuracy. These findings suggest men with cT2c disease should be offered treatment options for men with intermediate-risk CaP. As clinical staging more routinely incorporates MRI there is the potential to better identify bilateral organ-confined CaP and further establish risk classification.

Oncol, 2004

Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment
Anna C. Ferrari et al., J Clin Oncol, 2006

Fifteen year follow up of the first cohort of localized prostate cancer patients treated with brachytherapy
J. E. Sylvester, J Clin Oncol, 2016

Impact of Race on Prostate-Specific Antigen Outcome After Radical Prostatectomy for Clinically Localized Adenocarcinoma of the Prostate
Chaundre K. Cross et al., J Clin Oncol, 2002

Using the AUA/ASTRO Guideline on ART After Prostatectomy
Jung Hun Kang et al., Medscape, 2014

MEDLINE Abstracts:
Brachytherapy for Prostate Cancer

Medscape, 2003

MEDLINE Abstracts: Prostate Cancer Screening
Medscape, 2002

Metastasis After Radical

Prostatectomy Or External Beam
Radiotherapy For Patients With
Clinically Localized Prostate
Cancer

Medical News Today

Big Drop in Prostate Biopsies,
Prostatectomies in US

Kristin Jenkins et al., Medscape,
2016

Powered by

WHAT'S POPULAR

Most Read Most Cited

Minimal Residual Disease
Assessed by Multiparameter
Flow Cytometry in Multiple
Myeloma: Impact on Outcome
in the Medical Research
Council Myeloma IX Study
Rawstron et al.

Integration of Palliative Care
Into Standard Oncology Care:
American Society of Clinical
Oncology Clinical Practice
Guideline Update
Ferrell et al.

Use of Adjuvant

Bisphosphonates and Other
Bone-Modifying Agents in
Breast Cancer: A Cancer Care
Ontario and American Society
of Clinical Oncology Clinical
Practice Guideline
Dhesy-Thind et al.

Clinical Cancer Advances
2017: Annual Report on
Progress Against Cancer From
the American Society of
Clinical Oncology
Burstein et al.

Cabozantinib Versus Sunitinib
As Initial Targeted Therapy for
Patients With Metastatic Renal
Cell Carcinoma of Poor or
Intermediate Risk: The
Alliance A031203 CABOSUN
Trial
Choueiri et al.

JOURNAL OF
CLINICAL
ONCOLOGY

Journal of
oncology
practice

jgo
Journal of
Global Oncology

JCO™ | CLINICAL CANCER
INFORMATICS

JCO™ | PRECISION
ONCOLOGY

ASCO®



American Society of Clinical Oncology
2318 Mill Road, Suite 800, Alexandria, VA 22314
Journal of Clinical Oncology® is a trademark of the American Society of Clinical Oncology



[Contact us](#) | [Terms of Use](#) | [Privacy Policy](#)